Why is Hims & Hers Health (HIMS) stock down today?

Hims & Hers Health shares dropped 14.22% to $28.09 on July 24, 2026, after swinging through a wide intraday range of $27.92 to $34.57. The selloff appears to be a reversal following a dramatic overnight climb — the stock had surged after an FDA advisory panel backed four peptides, a positive regulatory signal for the telehealth company's compound-drug offerings. When a stock spikes sharply on news, it is common for traders to sell into the strength the following session, pulling the price back even as the underlying news remains favorable.

The FDA peptide decision was the dominant catalyst from the prior session. An FDA advisory panel endorsed four peptide compounds, which Hims & Hers markets through its telehealth platform. The ruling was widely described as a win for the company's long-term product strategy, and the stock climbed overnight on that news. However, today's trading reflects classic 'buy the rumor, sell the news' dynamics — the initial positive reaction gets unwound as short-term traders exit positions opened on the initial catalyst.

Adding a bearish counterweight, Martin Shkreli — a controversial figure in pharma circles — was reported to have taken a short position (a bet that the stock will fall) in HIMS, which may have added selling pressure. Meanwhile, Truist raised its price target on the stock to $27 from $23 but maintained a Hold rating, suggesting Wall Street sees limited upside at current prices despite the improved outlook. A SeekingAlpha analyst upgraded the stock to Buy citing the peptide ruling and operational discipline, but that positive view was not enough to offset profit-taking.

The broader market offered little support on the day, with the tech-heavy QQQ index falling 1.12% and the S&P 500 essentially flat at +0.05%. The company's last reported quarter showed revenue of $608.1 million but an EPS (earnings per share, or profit per share) loss of $0.40 against an estimate of roughly $0.03, a significant miss that continues to weigh on valuation debates. The next earnings report is scheduled for August 10, 2026, which will be the next major fundamental test for the stock.

As of the close, Hims & Hers carries a market cap of approximately $6.27 billion. The stock has risen roughly 313% over a longer recent period according to analyst commentary, leaving it exposed to sharp pullbacks even on broadly positive news days. The FDA peptide ruling remains a structural positive for the company's product pipeline, but today's decline reflects the gap between that longer-term story and near-term valuation pressures.